X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Anti-GD2 CAR NKT-Cell Therapy targeting BTG1 which is identified as a novel molecular target that can be used to enhance the potency of natural killer T (NKT)- and T cell-based cancer immunotherapy. It is being developed for relapsed/refractory neuroblastoma.
Lead Product(s): GINAKIT Cell Therapy,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Recipient: Immunai
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2023
Details:
TT11X (CD30.CAR-EBVST cells) utilizes CD30.CAR-modified Allogeneic Epstein-Barr Virus Specific T-Cell (EBVST) to target relapsed or refractory CD30-positive lymphomas.
Lead Product(s): CD30.CAR-EBVST Cells
Therapeutic Area: Oncology Product Name: TT11X
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Recipient: Tessa Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 07, 2022
Details:
Through this collaboration, BridgeBio will work with Baylor College of Medicine to identify and translate promising innovations into potential therapies for patients with genetically driven diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Recipient: BridgeBio Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 21, 2022
Details:
Zotatifin is a potent and sequence-selective inhibitor of eukaryotic translation initiation factor 4A (eIF4A) mediated translation used in solid tumor indications, including triple negative breast cancer.
Lead Product(s): Zotatifin
Therapeutic Area: Oncology Product Name: eFT226
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Effector Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2021
Details:
Zotatifin, is a small molecule inhibitor of eIF4A. eIF4A is a helicase responsible for unwinding complex secondary structures in “onco” mRNAs and enables select tumor cells to overproduce proteins associated with cellular growth.
Lead Product(s): Zotatifin
Therapeutic Area: Oncology Product Name: eFT226
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Effector Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2021
Details:
The Phase 1 safety study will test the safest maximum dose of L-citrulline for patients with MELAS. Once established, this dose will be used in a future clinical trial that will test the efficacy of L-citrulline.
Lead Product(s): Citrulline
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2021
Details:
The researchers used an experimental drug called MCB-613 within hours after heart attack in mouse models. The drug prompted the production of proteins called steroid receptor coactivators (SRCs).
Lead Product(s): MCB-613
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MCB-613
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
